GlassScriptPhysician profile
Bassel Kazkaz
NPI 1336196054
$344.98
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $103 · 2021: $13.14 · 2022: $29.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $77.02 | 2019-2020 | |
| Amgen INC. | $51.29 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.96 | 2019 | |
| Allergan, INC. | $40.84 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $39.62 | 2019 | |
| Lilly USA, LLC | $24.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.44 | 2019 | |
| Avion Pharmaceuticals | $17.27 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.84 | 2019 | |
| Celgene Corporation | $12.07 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Kazkaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.